Dulaglutide 0.75Mg/0.5Ml Inj Pen ( DrugBank: Dulaglutide )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04731272 (ClinicalTrials.gov) | April 20, 2021 | 26/1/2021 | GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance | Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults With Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a Randomized, Open-label, Cross-over Trial | Cystic Fibrosis;Pancreatic Insufficiency;Abnormal Glucose Tolerance;Diabetes | Drug: Dulaglutide 0.75Mg/0.5Ml Inj Pen | University of Pennsylvania | Children's Hospital of Philadelphia | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |